Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Addition of Lenvatinib to Pembrolizumab Fails to Improve Survival in Advanced Urothelial Carcinoma
The combination of lenvatinib and pembrolizumab elicited comparable antitumor activity compared with placebo plus pembrolizumab as frontline therapy in patients with advanced urothelial carcinoma who were ineligible for platinum-based chemotherapy, according to data from LEAP-011.
Continuous Enzalutamide After Progression Improves PFS in Patients with mCRPC
February 18th 2022Continuous enzalutamide plus docetaxel and prednisone elicited progression-free survival improvement vs placebo with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer who had previously progressed on enzalutamide alone
Darolutamide Plus ADT Boosts OS in Metastatic Castration-Sensitive Prostate Cancer
February 18th 2022The addition of darolutamide to androgen deprivation therapy and docetaxel generated better overall survival vs placebo with ADT and docetaxel in patients with metastatic castration-sensitive prostate cancer.
Frontline Niraparib Plus Abiraterone Improves rPFS in HRR Gene–Altered mCRPC
February 17th 2022The combination of niraparib and abiraterone acetate and prednisone led to a significant improvement in radiographic progression-free survival vs placebo plus abiraterone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
Olaparib/Abiraterone Combo Significantly Improves Radiographic PFS in mCRPC
Olaparib in combination with abiraterone acetate led to a 34% reduction in the risk of radiographic disease progression or death compared with placebo and abiraterone as a first-line treatment for patients with metastatic castration-resistant prostate cancer, according to results of the phase 3 PROpel trial.
Apalutamide Outperforms Enzalutamide in mCSPC in Real-World Analysis
A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.
Efforts to Effectively Target Rare Oncogenes Propel Progress in Lung Cancer
With 9 approved markers in non–small cell lung cancer and a plethora of established and emerging therapies that have been designed to target them, the need for molecular testing is more important than ever.
Emerging TKIs Shake Up the Treatment Landscape for EGFR Exon 20 Insertion+ NSCLC
Lyudmila Bazhenova, MD, explores key challenges faced with diagnosing and appropriately treating patients with non–small cell lung cancer that harbors EGFR exon 20 insertion mutations and provides insight into the second-line options that have recently garnered regulatory approval.
Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer
Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.
Repeat Molecular Testing Is Beneficial in EGFR+ NSCLC With Acquired Resistance
Repeat histologic evaluation and molecular testing in patients with EGFR-mutant non–small cell lung cancer who develop acquired resistance to osimertinib can deliver pertinent information that can help guide subsequent treatment decisions.
Abundance of Immunotherapy Combinations Leaves Treatment Selection Unclear in Advanced NSCLC
February 7th 2022Although PD-L1 expression and histology served as helpful stratification factors in pivotal trials, the paradigm will need to build out more tailored selection strategies as additional checkpoint inhibitors move through development.
Investigators Set Sights Beyond the PACIFIC Regimen in Unresectable Stage III NSCLC
February 7th 2022Concurrent chemoradiation followed by durvalumab has become the standard of care for patients with unresectable stage III non–small cell lung cancer based on the results of the phase 3 PACIFIC trial. However, several strategies are under clinical evaluation to push the paradigm beyond the PACIFIC regimen.
Neoadjuvant, Adjuvant Immunotherapies Poised to Revolutionize Outcomes in Resectable NSCLC
Surgical resection remains the key treatment modality for early-stage non–small cell lung cancer; however, both systemic adjuvant and neoadjuvant therapeutics are options that have value for patients.
Secondary Cytoreductive Surgery Requires Careful Selection in Recurrent Ovarian Cancer
Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.
